Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons with HIV infection and Compensated Advanced Chronic Liver Disease.
Human immunodeficiency virus (HIV)-infected individuals are at increased risk of cirrhosis and esophageal varices. Baveno VI criteria, based on liver stiffness measurement (LSM) and platelet count, have been proposed to avoid unnecessary esophagogastroduodenoscopy (EGD) screening for esophageal varices needing treatment (EVNT). This approach has not been validated in HIV-infected patients. HIV-infected patients from eight prospective cohorts were included if they fulfilled the following criteria: 1) compensated advanced chronic liver disease (LSM >10 kPa); 2) availability of EGD within 6 months of reliable LSM. Baveno VI (LSM <20 and platelets >150,000), expanded Baveno VI (LSM <25 and platelets >110,000) and HEPAVIR criteria (LSM <21) were applied to identify patients not requiring screening EGD. Criteria optimization was based on the percentage of EGD spared, while keeping the risk of missing EVNT below 5%. 507 HIV-infected patients were divided into a training (n=318) and a validation set (n=189). EVNT were found in 7.5%. In the training set, Baveno VI, expanded Baveno VI and HEPAVIR criteria spared 10.1%, 25.5% and 28% EGD, while missing 0%, 1.2% and 2.2% EVNT, respectively. The best thresholds to rule out EVNT were platelets >110,000 and LSM <30 kPa (HIV cirrhosis criteria), with 34.6% EGD spared and 0% EVNT missed. In the validation set, HEPAVIR and HIV cirrhosis criteria spared 54% and 48.7% EGD, while missing 4.9% and 2.2% EVNT, respectively. Baveno VI criteria can be extended to HEPAVIR and HIV cirrhosis criteria while sparing a significant number of EGD, thus improving resource utilization for HIV-related compensated advanced chronic liver disease.